UA74421C2 - Похідні індолону, які є антагоністами gal3 рецептора для лікування депресії і/або тривоги та композиції, придатні для такого лікування - Google Patents

Похідні індолону, які є антагоністами gal3 рецептора для лікування депресії і/або тривоги та композиції, придатні для такого лікування

Info

Publication number
UA74421C2
UA74421C2 UA2003088106A UA200388106A UA74421C2 UA 74421 C2 UA74421 C2 UA 74421C2 UA 2003088106 A UA2003088106 A UA 2003088106A UA 200388106 A UA200388106 A UA 200388106A UA 74421 C2 UA74421 C2 UA 74421C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutically acceptable
anxiety
depression
pyrimidine
subject
Prior art date
Application number
UA2003088106A
Other languages
English (en)
Russian (ru)
Inventor
Томас П. Блекберн
Майкл Конкель
Лакмал В. Ботеджу
Іан Джемі Талісман
Джон М. Ветцель
Матіванан Пакіараджан
Хейді Чен
Ермо Жименес
Бхарат Лагу
Кітає Лім
Стюарт Ноубл
Original Assignee
Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лундбекк А/С filed Critical Лундбекк А/С
Priority claimed from PCT/US2002/004608 external-priority patent/WO2002060392A2/en
Publication of UA74421C2 publication Critical patent/UA74421C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Даний винахід відноситься до похідних піримідину та індолону, які є селективними антагоністами рецептора GAL3; фармацевтичної композиції, що містить терапевтично ефективну кількість сполуки даного винаходу і фармацевтично прийнятний носій; фармацевтичної композиції, одержаної шляхом комбінування терапевтично ефективної кількості сполуки даного винаходу і фармацевтично прийнятного носія; способу одержання фармацевтичної композиції, який включає комбінування терапевтично ефективної кількості сполуки даного винаходу і фармацевтично прийнятного носія; способу лікування суб'єкта, який страждає депресією і/або станом тривоги, який включає введення суб'єкту кількості сполуки даного винаходу, ефективної при лікуванні депресії і/або тривоги у суб'єкта. Даний винахід також відноситься до способу лікування депресії і/або тривоги у суб'єкта, який включає введення суб'єкту композиції, що містить фармацевтично прийнятний носій і терапевтично ефективну кількість антагоніста рецептора GAL3.
UA2003088106A 2001-01-31 2002-01-31 Похідні індолону, які є антагоністами gal3 рецептора для лікування депресії і/або тривоги та композиції, придатні для такого лікування UA74421C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77534101A 2001-01-31 2001-01-31
PCT/US2002/004608 WO2002060392A2 (en) 2001-01-31 2002-01-31 Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Publications (1)

Publication Number Publication Date
UA74421C2 true UA74421C2 (uk) 2005-12-15

Family

ID=25104097

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003088106A UA74421C2 (uk) 2001-01-31 2002-01-31 Похідні індолону, які є антагоністами gal3 рецептора для лікування депресії і/або тривоги та композиції, придатні для такого лікування

Country Status (22)

Country Link
EP (3) EP1363638A4 (uk)
JP (3) JP4739650B2 (uk)
KR (1) KR20040041092A (uk)
CN (2) CN101406469B (uk)
AU (2) AU2002247149B2 (uk)
BG (1) BG108114A (uk)
BR (1) BR0206844A (uk)
CA (3) CA2438582C (uk)
CZ (1) CZ20032341A3 (uk)
EA (1) EA006486B1 (uk)
HR (1) HRP20030608A2 (uk)
HU (1) HUP0401858A3 (uk)
IL (2) IL157102A0 (uk)
IS (1) IS6880A (uk)
MX (1) MXPA03006812A (uk)
NO (1) NO20033388L (uk)
NZ (1) NZ527163A (uk)
PL (1) PL369270A1 (uk)
SK (1) SK9562003A3 (uk)
UA (1) UA74421C2 (uk)
YU (1) YU60803A (uk)
ZA (1) ZA200305686B (uk)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527163A (en) * 2001-01-31 2006-02-24 Synaptic Pharma Corp Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
MXPA04007612A (es) * 2002-02-05 2004-11-10 Novo Nordisk As Aril- y heteroarilpiperazinas novedosas.
CN101973925B (zh) * 2010-10-15 2012-03-28 中国药科大学 具有抗炎活性的2-吲哚酮类化合物、其制备方法及医药用途
ES2779152T3 (es) * 2013-10-07 2020-08-13 Kadmon Corporation Llc Derivados de (2-(5-isoindolin-2-il)pirimidin-4-il)-amina como inhibidores de Rho-quinasa para tratar enfermedades autoinmunes
JP7171057B2 (ja) 2016-12-29 2022-11-15 ミノリックス セラピューティクス エセ．エレ． ヘテロアリール化合物およびその使用
CA3127113A1 (en) * 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
CN113317221B (zh) * 2021-06-18 2023-01-31 青岛百宜电器有限公司 自动梳毛机

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50140441A (uk) * 1974-04-23 1975-11-11
GB1477349A (en) * 1975-09-24 1977-06-22 Ciba Geigy Ag Azo pigments
MA18829A1 (fr) * 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
US4946956A (en) * 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
JPH02300264A (ja) * 1989-05-16 1990-12-12 Fuji Photo Film Co Ltd アミノピリミジンアゾメチン色素とその製造方法
JPH02308248A (ja) * 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
HUT64323A (en) * 1992-06-09 1993-12-28 Richter Gedeon Vegyeszet Process for production new piperazinyl-bis(alkyl-amino)-pyrimidine derivatives
DK69693D0 (da) * 1993-06-14 1993-06-14 Neurosearch As Farven lilla
WO1995034540A1 (en) * 1994-06-15 1995-12-21 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
US6252104B1 (en) * 1995-04-12 2001-06-26 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Naphthol derivatives and process for producing the same
CZ378497A3 (cs) * 1995-06-02 1998-04-15 Synthelabo Deriváty oxazolidinonu, způsob jejich přípravy a jejich terapeutické použití
EP1000025B1 (en) * 1995-10-13 2007-02-21 Transitions Optical, Inc. Substituted naphthopyrans
FR2741072B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives d'oxazolidin-2-one, leur preparation et leur application en therapeutique
US6329197B2 (en) * 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
ES2172840T3 (es) * 1997-07-18 2002-10-01 Hoffmann La Roche Derivados de 5h-tiazolo(3,2-a)pirimidina.
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
CN1240210A (zh) * 1998-04-17 2000-01-05 伊莱利利公司 取代的三环化合物
AU770309B2 (en) * 1998-06-05 2004-02-19 Regent Court Technologies Monoamine oxidase (MAO) inhibitors and uses thereof
PE20001236A1 (es) * 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
CN1361768A (zh) * 1999-06-02 2002-07-31 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
WO2000076980A1 (fr) * 1999-06-10 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives heterocycliques azotes ou leurs sels
JP2003519143A (ja) * 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
NZ527163A (en) * 2001-01-31 2006-02-24 Synaptic Pharma Corp Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Also Published As

Publication number Publication date
ZA200305686B (en) 2004-10-25
AU2008200385B2 (en) 2010-09-09
AU2008200385A1 (en) 2008-02-21
KR20040041092A (ko) 2004-05-13
BG108114A (bg) 2005-03-31
PL369270A1 (en) 2005-04-18
NO20033388D0 (no) 2003-07-29
JP2010006813A (ja) 2010-01-14
CN101406469A (zh) 2009-04-15
IL157102A0 (en) 2004-02-08
CA2438582A1 (en) 2002-08-08
HRP20030608A2 (en) 2005-06-30
BR0206844A (pt) 2005-07-12
NZ527163A (en) 2006-02-24
SK9562003A3 (en) 2004-04-06
EP1363638A4 (en) 2010-01-06
HUP0401858A3 (en) 2009-06-29
EP1363638A2 (en) 2003-11-26
CZ20032341A3 (cs) 2004-12-15
EP2140862A3 (en) 2010-02-17
CN101406469B (zh) 2012-06-13
EA200300850A1 (ru) 2004-06-24
JP2004529089A (ja) 2004-09-24
JP2009173657A (ja) 2009-08-06
NO20033388L (no) 2003-09-24
MXPA03006812A (es) 2004-10-15
EP2140862A2 (en) 2010-01-06
IL198759A (en) 2013-06-27
EA006486B1 (ru) 2005-12-29
IS6880A (is) 2003-07-21
HUP0401858A2 (hu) 2004-12-28
EP2140864A3 (en) 2010-01-27
JP4739650B2 (ja) 2011-08-03
AU2002247149B2 (en) 2007-10-25
EP2140864A2 (en) 2010-01-06
CN1499970A (zh) 2004-05-26
CA2671776C (en) 2012-12-18
CA2438582C (en) 2012-06-26
CA2671776A1 (en) 2002-08-08
CA2672805A1 (en) 2002-08-08
YU60803A (sh) 2006-05-25
CN100446767C (zh) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
HK1082728A1 (en) Azabicyclo derivatives as muscarinic receptor antagonists
NZ522326A (en) Adenosine A2A receptor antagonists
JO2371B1 (en) 4-phenyl-pyridine derivatives
HK1098460A1 (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
ATE265419T1 (de) Spiro(2.4)heptanaminocarbonsäure und ihre derivate
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
MXPA02001340A (es) Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
HK1091200A1 (en) Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
AU6999796A (en) Heterocyclic compounds as bradykinin antagonists
GEP20074132B (en) Use of adenosine receptor a1 antagonists for treatment of pulmonary disease
UA74421C2 (uk) Похідні індолону, які є антагоністами gal3 рецептора для лікування депресії і/або тривоги та композиції, придатні для такого лікування
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
WO2004093789A3 (en) Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
MXPA04002389A (es) Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico.
DE69819166D1 (de) 8-substituierte-9h-1,3-dioxolo/4,5-h//2,3/benzodiazepin derivate als ampa/kainate-rezeptor-hemmer
WO2004014307A3 (en) Gal3 antagonists for the treatment of neuropathic pain
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
WO2004034967A3 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine